Zambon Completes Transformational Acquisition of Breath Therapeutics
Zambon, a multinational pharmaceutical company that focuses on innovation and development with the aim to improve the quality of people’s health and patients’ lives, announces the acquisition of Breath Therapeutics and its subsidiaries for € 140 million (up to total € 500 million subject to regulatory and sales milestones). The combination will improve both companies’ ability to better serve patients and healthcare professionals in severe respiratory diseases, as well as accelerate the commercialization of these important new therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190724005734/en/
ZAMBON RESPIRATORY TRACT NEW PIPELINE (Graphic: Business Wire)
Breath Therapeutics (BREATH), based in Munich, Germany and Menlo Park, California, US, is a biopharmaceutical company specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases with high unmet medical need. BREATH’s drug candidate is L‑CsA‑i, a novel proprietary liposomal formulation of Cyclosporine A, designed for inhaled administration with the drug-specific, investigational customized nebulizer from PARI. BREATH initiated two global phase III trials (BOSTON-1 and -2) in the US and Europe to evaluate L-CsA-i for the treatment of Bronchiolitis Obliterans Syndrome (BOS), a severe progressive lung disease with no approved therapies. It is estimated that there are over 30,000 people affected by BOS1. L-CsA-i has received orphan drug designation for the treatment of BOS from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), reflecting the high unmet need in addressing this disease. With financing in 2017 from its strong European investor syndicate, which includes Sofinnova Partners, Gimv and Gilde Healthcare, the BREATH team led L-CsA-i into global phase III trials, established a full commercial scale production for the drug and the device, and initiated commercial activities to prepare for and support future product launch.
BOS is a rapidly progressive disease that usually leads to respiratory failure and death within one to two years after diagnosis2. BOS is caused by an inflammatory process triggered by the immune system that irreversibly destroys the airways of the lungs. BOS most commonly affects people who have received lung or stem cell transplantation, although it is also associated with autoimmune disease and exposure to environmental contaminants. This disease is particularly devastating to those who have undergone complex transplants, as nearly 50 percent of that patient population develops BOS within five years after transplantation2.
Roberto Tascione, Chief Executive Officer at Zambon, commented:
“I am proud to announce the acquisition of Breath Therapeutics. This important deal, the largest in our history, reinforces Zambon’s commitment to serve severe respiratory diseases, enhancing and broadening our offering to the healthcare system, and complements our late-stage pipeline.
Bronchiolitis Obliterans Syndrome is an incredibly debilitating condition. Through the combination of our geographic footprint, R&D infrastructure and relationships with the scientific communities, we are well positioned to accelerate the development of an important new potential treatment and have the expertise in respiratory and the commercial capabilities to bring the product to patients and doctors as soon as possible.
As we want to identify, develop and offer innovative solutions for the treatment of severe life-altering diseases, this acquisition marks the start of a new phase for Zambon, not only for the great pipeline we’re acquiring but also for the scientific knowledge that the Breath Therapeutics team brings into our company.
I look forward to welcoming and working with our new colleagues, as together we can really maximise the potential of these life-changing products.”
Elena Zambon, President of Zambon, commented:
“It’s a pleasure to welcome in Zambon the Breath Therapeutics team. In a knowledge-based Company, as we are, with a long-term horizon, continuously focused on innovation, the most important asset are our people, their competences and expertise and, above all, their commitment to make patients’ lives better.
This acquisition is aligned to our core values and our vision to innovate cure and care. We are a “113 year old startup Company”, as I often say, with a strong heritage and tradition, aiming to enrich our pipeline with new relevant research projects to invest in the future for our patients and our people.”
Jens Stegemann, Chief Executive Officer of Breath Therapeutics, commented:
“At Breath Therapeutics, we have established L-CsA-i as a promising therapy for the treatment of BOS, with potential to impact patient lives. In Zambon, an ethical company with a strong heritage of innovation and a genuine commitment to a patient-orientated approach, we have a partner who shares our vision and significantly strengthens our position through their infrastructure, expertise and commitment to R&D. Together with the leading international lung transplantation centers participating in our BOSTON pivotal studies, we are now in an excellent position to achieve advances in the treatment of BOS.”
Zambon expects data from the L-CsA-i phase III clinical trials in 2021 and is confident that the drug will be ready for commercialization by 2023, subject to FDA and EMA regulatory approvals. Zambon’s expertise and resources will complement the Breath Therapeutics’ team as they become part of Zambon. Together, they will work to create an environment in which scientists feel comfortable developing new solutions and are able to drive meaningful change.
The acquisition of BREATH and its phase III asset, L-CsA-i for the treatment of BOS, complements Zambon’s existing pipeline in severe respiratory diseases and its presence in USA, which includes the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFBE), extending the company’s leadership in two rare respiratory conditions. Zambon recently received qualified infectious disease product (QIDP)3 and “Fast Track”4 designation from the FDA for colistimethate sodium powder for nebulizer solution via inhalation, in the prevention of pulmonary exacerbations in adult patients with NCFBE colonized with Pseudomonas aeruginosa. These important designations reinforce Zambon’s commitment to continue to develop a treatment against this disabling disease, with the aim of offering new options to patients and physicians.
-------------------------
1 Breath Therapeutics market research
2 The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report—2018; Focus theme: Multiorgan Transplantation. Chambers DC, et al. J Heart Lung Transplant; Volume 37, Issue 10,1169 – 1183
L-CsA-i and colistimethate sodium powder for nebulizer solution are investigational drugs and their safety and efficacy have not been established for the respective use described here.
Notes to Editors
About Zambon S.p.A.
Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. Based on a valuable heritage and strongly focused on the future, its goal is to improve people’s health through the development of innovative and quality healthcare solutions.
Zambon products are commercialized in 87 countries. The company has 20 subsidiaries in three different continents – Europe, America and Asia – and owns manufacturing units in Italy, Switzerland, China and Brazil. The company today has a strong focus on the treatment of rare diseases and specialties, on top of respiratory, pain management and women’s care. Zambon was established in 1906 in Italy and today counts around 2,500 employees all over the world. For further information, please visit www.zambon.com
About Breath Therapeutics
Founded in 2016, Breath Therapeutics is a private, venture-backed clinical stage biopharmaceutical company specializing in advanced inhaled therapeutics for severe respiratory diseases with high unmet medical need. In 2017, the company completed a Series A financing of USD 46 million with leading European investors, Sofinnova Partners, Gimv and Gilde Healthcare. Breath Therapeutics’ proprietary drug formulations have been specifically designed for inhaled administration with exclusively licensed, high performance nebulizer technology. L-CsA-i, Breath Therapeutics’ lead asset, is advancing as the first therapy for BOS, a rare and devastating lung disease with no currently available treatment. Breath Therapeutics has offices in Munich, Germany and Menlo Park, CA. For more information, please visit www.breath-therapeutics.com.
Liposomal Cyclosporine A for Inhalation (L-CsA-i)
Breath Therapeutics’ lead candidate, L-CsA-i, is a novel liposomal formulation of cyclosporine A designed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. Due to a narrow therapeutic window, mainly caused by nephrotoxicity, the systemic administration of CNIs cannot achieve sufficient drug levels in the bronchiolar tissue needed to treat BOS. L-CsA-i is administered via a customized drug-specific investigational eFlow® nebulizer from PARI Pharma (Germany). The drug-device combination is designed to deliver L-CsA-i to the site of disease in the lung while minimizing systemic exposure.
BOSTON Clinical Development Program
L-CsA-i is being developed for the treatment of BOS in patients age six and older. Five clinical trials are currently planned or underway. BOSTON-1 and BOSTON-2 are pivotal Phase III studies of patients with BOS following lung transplantation. BOSTON-3 is an open-label extension study for all study participants who complete BOSTON-1 or BOSTON-2. BOSTON-4 is a Phase 2 study and will be the first trial of L-CsA-i in adults with BOS following allogeneic hematopoietic stem cell transplant. BOSTON-5 is a Phase 2 study in pediatric patients with BOS.
Leopoldo Zambeletti acted as exclusive financial advisor to Breath Therapeutics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190724005734/en/
Contact information
Zambon Global Pharma Communications
Valentina Saffioti
valentina.saffioti@zambongroup.com
Tel. +39 02 6652 4508
FTI Consulting (media relations)
Brett Pollard/Victoria Foster Mitchell/Sam Purewal
Tel. +44 20 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investment in Identity Management Grows by 45 Percent Year-Over-Year, Highlighting its Increasing Importance to Organizations Globally17.9.2019 23:00:00 EEST | Press release
Optiv Security, in partnership with Momentum Cyber, has announced findings from its 2019 Security Technology Spend Insights Report, the leading barometer for evaluating technology buying trends. The report also includes Optiv’s top five technology trends and technology areas to watch, based on engagements with 7,000 Optiv clients across industries worldwide. The 2019 Security Technology Spend Insights Report examines the rise in spending on various security disciplines from 2017 to 2018: Identity Management Spending on Identity Management (IM) as a category grew by more than 45 percent Two subsets of IM saw significant individual growth as well, privileged access management (PAM) grew by 25% and Identity and Access Management (IAM) grew by over 55% Vulnerability Management and Email Security Spending on each grew by more than 30% Data Protection and Cloud Security Spending on each grew by more than 25% “While the strong spending growth on identity management is not surprising, the magni
Libelium’s IoT Technology Helps to Achieve the Sustainable Development Goals of the United Nations17.9.2019 22:00:00 EEST | Press release
Following the United Nations call for the Sustainable Development Goals (SDGs), Libelium promotes IoT technology as a tool to achieve prosperity while protecting the planet. Libelium values and encourages the prioritization of sustainability goals to maximize the impact that the IoT provides for a better world. Nowadays, IoT technology is contributing to the improvement of citizens’ quality of life and companies’ competitiveness. Investing in IoT technology directly impacts in manufacturing cost reduction, better use of natural resources preservation, product quality improvement and regulatory compliance. The report published by Libelium summarizes how IoT technology works in favour of the SDGs and which projects have been deployed worldwide according to each objective. Libelium has identified the benefits that IoT technology offers for goals such as zero hunger, good health, clean water, sustainable cities, industry, climate action, life on land and life below water. The objective of
LIWEST Becomes Latest Austrian Operator to Evolve IPTV Security with Verimatrix and Ocilion17.9.2019 20:31:00 EEST | Press release
IBC 2019 (#5.A59) – Verimatrix, (Paris:VMX), a global provider of security and business intelligence solutions that protect content, devices, applications and communications, today announced that LIWEST Kabelmedien has deployed Ocilion’s IPTV solutions integrated with Verimatrix security to enable more flexible and future-proof video delivery models. LIWEST joins kabelplus and Salzburg AG as the third Austrian operator to leverage the combined strengths of the partner companies in recent months. Facing a rise in streaming, LIWEST modernized its IPTV technology to stay at the forefront of a highly competitive market. The operator selected Ocilion and Verimatrix, recognizing how the partnership would essentially provide a flexible, one-stop shop solution. In addition to supporting set-top box (STB), tablet and smartphone delivery, the deployment marks a milestone for Ocilion in enabling Amazon Fire TV and Apple TV streaming. “As Austrian subscriber behaviors shift away from traditional l
Compute Express Link Consortium (CXL) Officially Incorporates; Announces Expanded Board of Directors17.9.2019 19:34:00 EEST | Press release
Today, Alibaba, Cisco, Dell EMC, Facebook, Google, Hewlett Packard Enterprise, Huawei, Intel Corporation and Microsoft announce the incorporation of the Compute Express Link (CXL) Consortium, and unveiled the names of its newly-elected members to its Board of Directors. The core group of key industry partners announced their intent to incorporate in March 2019, and remain dedicated to advancing the CXL standard, a new high-speed CPU-to-Device and CPU-to-Memory interconnect which accelerates next-generation data center performance. The five new CXL board members are as follows: Steve Fields, Fellow and Chief Engineer of Power Systems, IBM; Gaurav Singh, Corporate Vice President, Xilinx; Dong Wei, Standards Architect and Fellow at ARM Holdings; Nathan Kalyanasundharam, Senior Fellow at AMD Semiconductor; and Larrie Carr, Fellow, Technical Strategy and Architecture, Data Center Solutions, Microchip Technology Inc. Chairman of the CXL Consortium, Jim Pappas, discussed the recent developmen
Community Welcomes Two New Premium Media Brands17.9.2019 19:00:00 EEST | Press release
Community, powered by Xandr, welcomes two additional premium media brands; Bloomberg and Vudu, building upon previously announced partners. Current Community partners include, WarnerMedia’s CNN, TNT, TBS, truTV, B/R Live, Otter Media, and Warner Bros., as well as A+E Networks, AMC Networks, Cheddar, VICE, Hearst Magazines, Newsy, Philo, Tubi, and Xumo. Built on Xandr’s powerful technology and consumer insights, Community simplifies and enhances an advertiser’s connection to unique audiences. Community enables advertisers to reach their audiences at scale in a brand-safe, privacy-protected, and premium video environment. “Community is successful because of its partners and the premium content they produce every day,” said Brian Lesser, CEO of Xandr. “Together with our Community partners, we are helping advertisers reach interested consumers on whatever device they watch their favorite show. With Xandr’s powerful technology and unique consumer insights, combined with the best content in
EP Henry Introduces World’s First Precast Products Manufactured with CO2-Cured Solidia Concrete17.9.2019 18:40:00 EEST | Press release
EP Henry, the leading manufacturer of unit concrete products in North America, in collaboration with Solidia Technologies®, a cement and concrete technology start-up, has introduced the world’s first products made with low-carbon Solidia Concrete™. Using LafargeHolcim’s Solidia Cement™ as its base, which requires lower temperatures during production and thereby emits less carbon, Solidia Concrete products are cured with CO2 instead of water, reducing their overall carbon footprint up to 70% compared to traditional concrete. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005888/en/ EP Henry's CO2-cured Solidia Concrete™ pavers made from low-carbon Solidia Cement™ at the Elsmere, Delaware Fire Company (Photo: Business Wire) “Our reputation as the leader in the industry has led to some significant partnerships in new product and technology development,” said EP Henry President Eric Long. “This most recent—and perhaps most
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom